ATE418992T1 - Verwendung von tgf-beta2 antisense oligonukleotiden - Google Patents
Verwendung von tgf-beta2 antisense oligonukleotidenInfo
- Publication number
- ATE418992T1 ATE418992T1 AT06755024T AT06755024T ATE418992T1 AT E418992 T1 ATE418992 T1 AT E418992T1 AT 06755024 T AT06755024 T AT 06755024T AT 06755024 T AT06755024 T AT 06755024T AT E418992 T1 ATE418992 T1 AT E418992T1
- Authority
- AT
- Austria
- Prior art keywords
- tgf
- antisense oligonucleotides
- oligonucleotide
- beta3
- beta1
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 abstract 2
- 102000003814 Interleukin-10 Human genes 0.000 abstract 2
- 108090000174 Interleukin-10 Proteins 0.000 abstract 2
- 102100027584 Protein c-Fos Human genes 0.000 abstract 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 abstract 2
- 102100023132 Transcription factor Jun Human genes 0.000 abstract 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 abstract 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 abstract 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 abstract 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 2
- 229960002986 dinoprostone Drugs 0.000 abstract 2
- 229940076144 interleukin-10 Drugs 0.000 abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 2
- 101150082674 E2 gene Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05009802 | 2005-05-05 | ||
| US68049305P | 2005-05-13 | 2005-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE418992T1 true ATE418992T1 (de) | 2009-01-15 |
Family
ID=36370983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06755024T ATE418992T1 (de) | 2005-05-05 | 2006-05-04 | Verwendung von tgf-beta2 antisense oligonukleotiden |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8097597B2 (de) |
| EP (2) | EP1877070B1 (de) |
| JP (2) | JP4977035B2 (de) |
| AT (1) | ATE418992T1 (de) |
| AU (2) | AU2006243218B2 (de) |
| BR (1) | BRPI0611452A2 (de) |
| CA (1) | CA2591586A1 (de) |
| CY (1) | CY1108944T1 (de) |
| DE (1) | DE602006004578D1 (de) |
| DK (1) | DK1877070T3 (de) |
| ES (1) | ES2319332T3 (de) |
| MX (1) | MX2007007184A (de) |
| NZ (1) | NZ562954A (de) |
| PL (1) | PL1877070T3 (de) |
| PT (1) | PT1877070E (de) |
| RU (1) | RU2427377C2 (de) |
| SI (1) | SI1877070T1 (de) |
| WO (1) | WO2006117400A2 (de) |
| ZA (2) | ZA200709237B (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE418992T1 (de) | 2005-05-05 | 2009-01-15 | Antisense Pharma Gmbh | Verwendung von tgf-beta2 antisense oligonukleotiden |
| EP1935428A1 (de) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonukleotid-Polymer Konjugate |
| US8822425B2 (en) | 2008-11-14 | 2014-09-02 | Antisense Pharma Gmbh | Dosage of oligonucleotides suitable for the treatment of tumors |
| WO2010055148A2 (en) * | 2008-11-14 | 2010-05-20 | Antisense Pharma Gmbh | Dosage of oligonucleotides suitable for the treatment of tumors |
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| SG10201403841QA (en) | 2009-07-06 | 2014-09-26 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| EP2453017A1 (de) * | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotide zur Verwendung bei der Prophilaxe und/oder Behandlung von TGF-beta1- und TGF-beta2-, TGF-beta2- und TGF-beta3-, TGF-beta1- und TGF-beta3- oder TGF-beta1-, TGF-beta2- und TGF-beta3-mRNA-Überexpressionskrankheiten |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| EP2872147B1 (de) | 2012-07-13 | 2022-12-21 | Wave Life Sciences Ltd. | Verfahren zur herstellung von chiralen oligonukleotiden |
| RU2693381C2 (ru) | 2012-07-13 | 2019-07-02 | Уэйв Лайф Сайенсес Лтд. | Асимметричная вспомогательная группа |
| WO2014010718A1 (ja) | 2012-07-13 | 2014-01-16 | 株式会社新日本科学 | キラル核酸アジュバント |
| AU2014317961B2 (en) * | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| EP3095459A4 (de) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chirales nukleinsäureadjuvans mit antitumorwirkung und antitumormittel |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| CA2936712A1 (en) | 2014-01-16 | 2015-07-23 | Meena | Chiral design |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
| KR102680316B1 (ko) * | 2021-11-01 | 2024-07-01 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| EP0348458B1 (de) | 1987-11-30 | 1997-04-09 | University Of Iowa Research Foundation | Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| TW244371B (de) | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| EP1160319A3 (de) | 1993-04-30 | 2002-03-06 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Antisense Oligonukleotide zur Behandlung von Immunosuppressive Wirkungen von TGF-beta |
| US6455689B1 (en) * | 1993-04-30 | 2002-09-24 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Antisense-oligonucleotides for transforming growth factor-β (TGF-β) |
| DK0626387T3 (da) | 1993-05-12 | 1999-09-27 | Novartis Ag | Nukleosider og oligonukleotider med 2'-ethergrupper |
| US7326783B2 (en) * | 1993-07-10 | 2008-02-05 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms |
| US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
| DE69523680T2 (de) | 1994-08-02 | 2002-08-14 | Olympus Optical Co., Ltd. | Endoskopische Fassvorrichtung |
| US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| EP0856579A1 (de) | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden |
| ES2226414T3 (es) | 1998-06-10 | 2005-03-16 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Estimulacion del sistema inmunitario. |
| EP1133988A1 (de) | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mischung enthaldend einen Inhibitor oder Suppressor von einen Gens und eine Moleküle bindende des Expressionprodukt des Gens |
| US7963956B2 (en) * | 2003-04-22 | 2011-06-21 | Antisense Pharma Gmbh | Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique |
| CA2550058C (en) * | 2003-12-19 | 2016-07-12 | Antisense Pharma Gmbh | Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic |
| JP5650367B2 (ja) * | 2004-02-27 | 2015-01-07 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
| ATE418992T1 (de) | 2005-05-05 | 2009-01-15 | Antisense Pharma Gmbh | Verwendung von tgf-beta2 antisense oligonukleotiden |
-
2006
- 2006-05-04 AT AT06755024T patent/ATE418992T1/de active
- 2006-05-04 AU AU2006243218A patent/AU2006243218B2/en not_active Ceased
- 2006-05-04 DE DE602006004578T patent/DE602006004578D1/de active Active
- 2006-05-04 EP EP06755024A patent/EP1877070B1/de active Active
- 2006-05-04 NZ NZ562954A patent/NZ562954A/en not_active IP Right Cessation
- 2006-05-04 RU RU2007145046/15A patent/RU2427377C2/ru not_active IP Right Cessation
- 2006-05-04 BR BRPI0611452-0A patent/BRPI0611452A2/pt not_active Application Discontinuation
- 2006-05-04 MX MX2007007184A patent/MX2007007184A/es active IP Right Grant
- 2006-05-04 US US11/792,041 patent/US8097597B2/en not_active Expired - Fee Related
- 2006-05-04 SI SI200630221T patent/SI1877070T1/sl unknown
- 2006-05-04 ZA ZA200709237A patent/ZA200709237B/xx unknown
- 2006-05-04 ES ES06755024T patent/ES2319332T3/es active Active
- 2006-05-04 CA CA002591586A patent/CA2591586A1/en not_active Abandoned
- 2006-05-04 PL PL06755024T patent/PL1877070T3/pl unknown
- 2006-05-04 DK DK06755024T patent/DK1877070T3/da active
- 2006-05-04 PT PT06755024T patent/PT1877070E/pt unknown
- 2006-05-04 JP JP2007551691A patent/JP4977035B2/ja not_active Expired - Fee Related
- 2006-05-04 WO PCT/EP2006/062067 patent/WO2006117400A2/en not_active Ceased
- 2006-05-04 EP EP08173070.7A patent/EP2062586B1/de active Active
-
2008
- 2008-10-31 ZA ZA2008/09354A patent/ZA200809354B/en unknown
-
2009
- 2009-03-27 CY CY20091100366T patent/CY1108944T1/el unknown
- 2009-12-10 JP JP2009280553A patent/JP2010090159A/ja active Pending
- 2009-12-17 AU AU2009251023A patent/AU2009251023B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2319332T3 (es) | 2009-05-06 |
| NZ562954A (en) | 2009-10-30 |
| JP4977035B2 (ja) | 2012-07-18 |
| ZA200809354B (en) | 2010-02-24 |
| EP1877070A2 (de) | 2008-01-16 |
| PL1877070T3 (pl) | 2009-06-30 |
| JP2008528460A (ja) | 2008-07-31 |
| EP1877070B1 (de) | 2008-12-31 |
| RU2427377C2 (ru) | 2011-08-27 |
| US8097597B2 (en) | 2012-01-17 |
| AU2009251023A1 (en) | 2010-01-14 |
| CY1108944T1 (el) | 2014-07-02 |
| PT1877070E (pt) | 2009-03-13 |
| WO2006117400A2 (en) | 2006-11-09 |
| EP2062586A3 (de) | 2009-08-12 |
| ZA200709237B (en) | 2009-04-29 |
| DE602006004578D1 (de) | 2009-02-12 |
| EP2062586A2 (de) | 2009-05-27 |
| AU2006243218A1 (en) | 2006-11-09 |
| US20090306176A1 (en) | 2009-12-10 |
| CA2591586A1 (en) | 2006-11-09 |
| AU2006243218B2 (en) | 2009-09-17 |
| RU2007145046A (ru) | 2009-06-10 |
| MX2007007184A (es) | 2008-01-14 |
| WO2006117400A3 (en) | 2007-01-25 |
| AU2009251023B2 (en) | 2012-02-02 |
| DK1877070T3 (da) | 2009-03-02 |
| EP2062586B1 (de) | 2017-03-15 |
| JP2010090159A (ja) | 2010-04-22 |
| SI1877070T1 (sl) | 2009-06-30 |
| BRPI0611452A2 (pt) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE418992T1 (de) | Verwendung von tgf-beta2 antisense oligonukleotiden | |
| AR039717A1 (es) | Construcciones de arn de intrones cadena doble y usos de las mismas | |
| EA201100907A1 (ru) | Композиции и способы ингибирования экспрессии гена pcsk9 | |
| WO2006110688A3 (en) | Rnai therapeutic for respiratory virus infection | |
| ATE476441T1 (de) | Wirksame lna-oligonukleotide zur inhibierung von hif-1a | |
| ATE528008T1 (de) | Rnai-modulation von aha und ihre therapeutische verwendung | |
| JP2015142558A5 (de) | ||
| SI3222724T1 (sl) | Nadaljnje nove oblike molekul interferenčne RNA | |
| NO20084738L (no) | Forbindelser og fremgangsmater for modulering av ekspresjonen av PCSK9 | |
| ATE460481T1 (de) | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung | |
| NZ593618A (en) | Gnaq targeted dsrna compositions and methods for inhibiting expression | |
| WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
| WO2007128477A3 (en) | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION | |
| WO2005081714A3 (en) | Use of interfering rna in the production of transgenic animals | |
| WO2007115168A8 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
| ATE522607T1 (de) | Sense-oligonukleotid mit fähigkeit zur kontrolle der expression von inos sowie dieses umfassende zusammensetzung | |
| MX2009002462A (es) | Siarn y metodos de manufactura del mismo. | |
| WO2008036638A3 (en) | Rnai modulation of scap and therapeutic uses thereof | |
| WO2007127919A3 (en) | Compositions and methods for inhibiting expression of a gene from the jc virus | |
| RU2013102545A (ru) | Связывающая vegfa си-рнк и способы лечения in vivo | |
| WO2007137220A3 (en) | Compositions and methods for inhibiting expression of ikk-b gene | |
| WO2005001031A3 (en) | Modulation of the rna interference pathway | |
| ATE510545T1 (de) | Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen | |
| WO2004015117A3 (en) | Targeted gene modification by single-stranded dna oligonucleotides | |
| ATE498688T1 (de) | Dna, welche für eine pflanzliche deoxyhypusine synthase und einen pflanzlichen eukaryotischen initiationsfaktor 5a kodiert; transgene pflanzen und verfahren zum kontrollieren der seneszenz und des programmierten zelltods in pflanzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1877070 Country of ref document: EP |